Cargando…
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard treatment for metastatic castration resistant prostate cancer (mCRPC), but it inevitably leads to the development of resistance. Since the introduction of highly efficient AR signalling inhibitors, approximate...
Autores principales: | Handle, Florian, Prekovic, Stefan, Helsen, Christine, Van den Broeck, Thomas, Smeets, Elien, Moris, Lisa, Eerlings, Roy, Kharraz, Sarah El, Urbanucci, Alfonso, Mills, Ian G., Joniau, Steven, Attard, Gerhardt, Claessens, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760229/ https://www.ncbi.nlm.nih.gov/pubmed/31551480 http://dx.doi.org/10.1038/s41598-019-50220-1 |
Ejemplares similares
-
Comparing the rules of engagement of androgen and glucocorticoid receptors
por: Claessens, Frank, et al.
Publicado: (2017) -
Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021) -
A disease‐associated missense mutation in CYP4F3 affects the metabolism of leukotriene B4 via disruption of electron transfer
por: Smeets, Elien, et al.
Publicado: (2022) -
RF03 | PMON286 Engineering Steroid Receptors to Respond to Chemicals of Choice
por: Claessens, Frank, et al.
Publicado: (2022) -
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)